Literature DB >> 19464259

Involvement of TRPC3 channels in calcium oscillations mediated by OX(1) orexin receptors.

Hanna M Peltonen1, Johanna M Magga, Genevieve Bart, Pauli M Turunen, Miia S H Antikainen, Jyrki P Kukkonen, Karl E Akerman.   

Abstract

Oscillations of intracellular Ca2+ provide a novel mechanism for sustained activation of cellular processes. Receptor-activated oscillations are mainly thought to occur through rhythmic IP3-dependent store discharge. However, as shown here in HEK293 cells 1 nM orexin-A (Ox-A) acting at OX1 receptors (OX1R) triggered oscillatory Ca2+ responses, requiring external Ca2+. These responses were attenuated by interference with TRPC3 channel (but not TRPC1/4) function using dominant negative constructs, elevated Mg2+ (a blocker of many TRP channels) or inhibition of phospholipase A2. These treatments did not affect Ca2+ oscillations elicited by high concentrations of Ox-A (100 nM) in the absence of external Ca2+. OX1R are thus able to activate TRPC(3)-channel-dependent oscillatory responses independently of store discharge.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464259     DOI: 10.1016/j.bbrc.2009.05.077

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

2.  Orexin/hypocretin receptor signalling: a functional perspective.

Authors:  C S Leonard; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 3.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

Review 4.  Role of orexin receptors in obesity: from cellular to behavioral evidence.

Authors:  C E Perez-Leighton; T A Butterick-Peterson; C J Billington; C M Kotz
Journal:  Int J Obes (Lond)       Date:  2012-03-06       Impact factor: 5.095

5.  Orexin/hypocretin activates mTOR complex 1 (mTORC1) via an Erk/Akt-independent and calcium-stimulated lysosome v-ATPase pathway.

Authors:  Zhiqiang Wang; Shimeng Liu; Miyo Kakizaki; Yuuki Hirose; Yukiko Ishikawa; Hiromasa Funato; Masashi Yanagisawa; Yonghao Yu; Qinghua Liu
Journal:  J Biol Chem       Date:  2014-10-02       Impact factor: 5.157

Review 6.  The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs.

Authors:  Marc Laburthe; Thierry Voisin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  OX1 orexin/hypocretin receptor activation of phospholipase D.

Authors:  M H Jäntti; J Putula; P Somerharju; M A Frohman; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 8.  Orexin/hypocretin receptor signalling cascades.

Authors:  J P Kukkonen; C S Leonard
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

9.  Orexin A stimulates glucose uptake, lipid accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes.

Authors:  M Skrzypski; T T Le; P Kaczmarek; E Pruszynska-Oszmalek; P Pietrzak; D Szczepankiewicz; P A Kolodziejski; M Sassek; A Arafat; B Wiedenmann; K W Nowak; M Z Strowski
Journal:  Diabetologia       Date:  2011-04-21       Impact factor: 10.122

10.  Orexin receptors in GtoPdb v.2021.3.

Authors:  Paul Coleman; Luis de Lecea; Anthony Gotter; Jim Hagan; Daniel Hoyer; Thomas Kilduff; Jyrki P Kukkonen; Rod Porter; John Renger; Jerome M Siegel; Gregor Sutcliffe; Neil Upton; Christopher J Winrow
Journal:  IUPHAR BPS Guide Pharm CITE       Date:  2021-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.